| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5693803 | European Urology | 2017 | 7 Pages |
Abstract
We established a method for determining AR-V7 status in whole blood. This test predicted treatment resistance in patients with metastatic castration-resistant prostate cancer undergoing treatment with abiraterone or enzalutamide. Prospective validation is needed before application to clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen E. Gschwend, Jürgen Ruland, Christof Winter, Matthias M. Heck,